Penumbra (NASDAQ: ATRS) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Penumbra and Antares Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Penumbra 0 2 4 0 2.67
Antares Pharma 0 0 2 0 3.00

Penumbra currently has a consensus price target of $160.00, indicating a potential upside of 27.29%. Antares Pharma has a consensus price target of $4.50, indicating a potential upside of 32.74%. Given Antares Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Antares Pharma is more favorable than Penumbra.

Profitability

This table compares Penumbra and Antares Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Penumbra 7.19% 2.78% 2.35%
Antares Pharma -35.53% -64.96% -26.68%

Volatility & Risk

Penumbra has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

Earnings & Valuation

This table compares Penumbra and Antares Pharma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Penumbra $333.76 million 12.95 $4.65 million ($0.01) -12,570.00
Antares Pharma $54.51 million 9.79 -$16.74 million ($0.11) -30.82

Penumbra has higher revenue and earnings than Antares Pharma. Penumbra is trading at a lower price-to-earnings ratio than Antares Pharma, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.1% of Penumbra shares are owned by institutional investors. Comparatively, 38.3% of Antares Pharma shares are owned by institutional investors. 10.7% of Penumbra shares are owned by company insiders. Comparatively, 12.2% of Antares Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Penumbra beats Antares Pharma on 9 of the 14 factors compared between the two stocks.

About Penumbra

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.

About Antares Pharma

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc., as well as a development agreement with Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.